Jump to content

Otsuka Pharmaceutical: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
SdkbBot (talk | contribs)
Bots
356,382 edits
m General fixes, removed erroneous space
Jnana acquisition
 
(24 intermediate revisions by 17 users not shown)
Line 2: Line 2:
{{Expand Japanese|大塚製薬|date=March 2020}}
{{Expand Japanese|大塚製薬|date=March 2020}}
{{Infobox company
{{Infobox company
| name = Otsuka Pharmaceutical Co., Ltd.
| name = Otsuka Pharmaceutical Co., Ltd.
| logo = Otsuka Holdings logo.svg
| logo = Otsuka Holdings logo.svg
| caption =
| caption =
| image =
| image =
| image_caption =
| image_caption =
| trading_name =
| trading_name =
| native_name = 大塚製薬株式会社
| native_name = 大塚製薬株式会社
| native_name_lang = ja
| native_name_lang = ja
| romanized_name = Ōtsuka Seiyaku Kabushiki-gaisha
| romanized_name = Ōtsuka Seiyaku Kabushiki-gaisha
| former_name =
| former_name =
| type = [[Public company|Public]] [[Kabushiki gaisha|KK]]
| type = [[Public company|Public]] [[Kabushiki gaisha|KK]]
| traded_as = {{TYO|4578}}<br>[[TOPIX|TOPIX 100 Component]]
| traded_as = {{TYO|4578}}<br>[[TOPIX|TOPIX 100 Component]]
| ISIN =
| ISIN =
| industry = [[Pharmaceutical industry|Pharmaceutical]]
| industry = [[Pharmaceutical industry|Pharmaceutical]]
| genre =
| genre =
| fate =
| fate =
| predecessor =
| predecessor =
| successor =
| successor =
| foundation = 1921 (Originally founded), 1964 (Current corporation)
| foundation = {{Start date and age|1921}} (Founded)<br >1964 (Incorporated)
| founder = Busaburo Otsuka
| founder = Busaburo Otsuka
| defunct =
| defunct =
| location_city = [[Chiyoda, Tokyo|Chiyoda]], [[Tokyo]]
| location_city = [[Chiyoda, Tokyo|Chiyoda]], [[Tokyo]]
| location_country = [[Japan]]
| location_country = [[Japan]]
| location =
| location =
| coordinate =
| coordinate =
| locations = 69
| locations = 69
| area_served = Worldwide
| area_served = Worldwide
| key_people = Tatsuo Higuchi <small>([[President (corporate title)|President]])</small>
| key_people = Tatsuo Higuchi <small>([[President (corporate title)|President]])</small>
| products =
| products =
| brands =
| brands =
| production =
| production =
| production_year =
| production_year =
| services = <!--サービス-->
| services = <!--サービス-->
| revenue = ¥ 531.2 billion
| revenue = ¥ 1.74 trillion
| revenue_year = 2017
| revenue_year = 2022
| operating_income = ¥ 57.0 billion
| operating_income = ¥ 150.32 billion
| income_year = 2017
| income_year = 2022
| net_income =
| net_income =
| net_income_year =
| net_income_year =
| aum =
| aum =
| assets =
| assets =
| assets_year =
| assets_year =
| equity =
| equity =
| equity_year =
| equity_year =
| owner = [[Nomura Trust and Banking]] [[investment trusts]] (11.43%)<br>''and investment trusts managed by other banks''
| owner = [[Nomura Trust and Banking]] [[investment trusts]] (11.43%)<br>''and investment trusts managed by other banks''
| num_employees = 5,634
| num_employees = 5,634
| num_employees_year = 2017
| num_employees_year = 2017
| parent = Otsuka Holdings Co. Ltd
| parent = Otsuka Holdings Co. Ltd
| divisions =
| divisions =
| subsid =
| subsid =
| homepage = [http://www.otsuka.com/en/ otsuka.com]
| homepage = [http://www.otsuka.com/en/ otsuka.com]
| footnotes =
| footnotes =
}}
}}
⚫
[[File:Products of Otsuka Pharmaceutical.jpg|thumb|Products of Otsuka Pharmaceutical]]
{{nihongo|'''Otsuka Pharmaceutical Co., Ltd.'''|大塚製薬株式会社|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[Naruto, Tokushima|Naruto]], [[Japan]]. The company was established August 10, 1964.
{{nihongo|'''Otsuka Pharmaceutical Co., Ltd.'''|大塚製薬株式会社|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[Naruto, Tokushima|Naruto]], [[Japan]]. The company was established August 10, 1964.


==History==
==History==
OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]].<ref name=fujitoslodkowski2010/> The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.<ref name=fujitoslodkowski2010>{{Citation |last1=Fujita |first1=Junko |first2=Antoni |last2=Slodkowski |editor=Nathan Layne |date=December 16, 2010 |publisher=[[Forexyard]] |access-date=January 15, 2012 |title=Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 |type=[[Reuters]] news |at=forexyard.com |url=http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |url-status=dead |archive-url=https://web.archive.org/web/20120304221059/http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |archive-date=March 4, 2012 }}</ref>
OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]].<ref name=fujitoslodkowski2010/> The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.<ref name="fujitoslodkowski2010">{{Cite news |last1=Fujita |first1=Junko |last2=Slodkowski |first2=Antoni |date=December 16, 2010 |title=Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 |agency=Reuters |editor-last=Layne |editor-first=Nathan |url=http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |url-status=dead |access-date=January 15, 2012 |archive-url=https://web.archive.org/web/20120304221059/http://www.forexyard.com/en/news/Otsuka-up-5-pct-in-Tokyo-debut-after-24-bln-IPO-2010-12-15T005127Z-UPDATE-1 |archive-date=March 4, 2012}}</ref>


=== Otsuka Pharmaceutical Co. LTD Holdings ===
===Otsuka Pharmaceutical Co. Ltd Holdings===
⚫
In 1955, the company started a [[football (soccer)|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto.<ref>{{cite web |title=Tokushima Vortis |date=15 January 2020 |url=https://lostinfootballjapan.com/club-profiles/tokushima-vortis/ |access-date=October 30, 2020}}</ref>

⚫
In 1955, the company started a [[football (soccer)|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto.<ref>{{cite web |title=Tokushima Vortis |url=https://lostinfootballjapan.com/club-profiles/tokushima-vortis/ |access-date=October 30, 2020}}</ref>


In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]].<ref>{{cite web |title=Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A. |url=https://www.otsuka.co.jp/en/company/newsreleases/2008/20080528_1.html |website=otsuka.co.jp |access-date=October 30, 2020 |date=May 28, 2008}}</ref>
In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]].<ref>{{cite web |title=Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A. |url=https://www.otsuka.co.jp/en/company/newsreleases/2008/20080528_1.html |website=otsuka.co.jp |access-date=October 30, 2020 |date=May 28, 2008}}</ref>


⚫
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".<ref>{{Citation |date=January 13, 2012 |publisher=BioSpace |title=Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead |url=http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |access-date=January 15, 2012 |archive-url=https://web.archive.org/web/20160303182456/http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |archive-date=March 3, 2016 |url-status=dead }}</ref> This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.<ref>{{Citation |date=January 13, 2012 |access-date=January 15, 2012|title=UCB and Otsuka to focus collaboration on CNS disorders |publisher=Zenopa|url=http://www.zenopa.com/news/801263654/UCB_and_Otsuka_to_focus_collaboration_on_CNS_disorders }}</ref>
⚫
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|access-date=23 April 2018}}</ref>


⚫
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref>
⚫
In July 2017, they bought [[Daiya]]<ref>{{Cite web|url=https://www.fooddive.com/news/plant-based-food-firm-daiya-bought-for-32597m-by-pharma-company-otsuka/448160/|title=Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka|website=Food Dive}}</ref>


In July 2018, Otsuka agreed to acquire Visterra for $430 million cash.<ref>{{Cite web|url=https://www.genengnews.com/topics/drug-discovery/otsuka-to-acquire-visterra-for-430m-adding-to-its-pipeline-and-platforms/|title=Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms|date=July 11, 2018}}</ref>
In 2023, the company announced the acquisition of Mindset Pharma for $58.6 million.<ref name=cen2023>{{cite news|url=https://cen.acs.org/business/mergers-&-acquisitions/Otsuka-buy-Mindset-Pharma/101/i30|title=Otsuka to buy Mindset Pharma|last=Howes|first=Laura|work=[[Chemical & Engineering News]]|date=September 9, 2023|access-date=June 1, 2024}}</ref>

===Acquisition history===
{{hidden begin|border=1px #aaa solid|title=Otsuka Pharmaceutical Acquisitions|ta1=center}}
{{Tree list}}
* '''Otsuka Pharmaceutical Co., Ltd'''
** [[Ridge Vineyards]] <small>(Acq 1986)</small><ref>{{cite web | url=https://www.otsuka.co.jp/en/company/otsuka-people-talk/13.html | title=Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 &#124; Otsuka People Talk }}</ref>
⚫
** [[Crystal Geyser Water Company]] <small>(Acq 1990)</small><ref>[https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library] {{Webarchive|url=https://web.archive.org/web/20190616203733/https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf |date=2019-06-16 }}, ''Otsuka Pharmaceutical''. Retrieved September 21, 2019.</ref>
⚫
** [[Astex Pharmaceuticals]] <small>(Merged 2011, Acq 2013)</small><ref>{{cite news| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905| title=Japan's Otsuka to buy U.S. cancer firm Astex for $886 million| first=Tim| last=Kelly| work=Reuters| date=September 5, 2013 }}</ref>
*** Astex Therapeutics Limited
*** SuperGen, Inc
⚫
** [[Avanir Pharmaceuticals]] <small>(Acq 2014)</small><ref>{{cite web|url=https://dealbook.nytimes.com/2014/12/02/otsuka-of-japan-to-buy-avanir-pharmaceuticals-for-3-5-billion/?module=BlogPost-Title&version=Blog+Main&contentCollection=Mergers+&+Acquisitions&action=Click&pgtype=Blogs&region=Body|title=Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion|first=Jonathan|last=Soble|website=[[The New York Times]]|date=2 December 2014 |access-date=23 April 2018}}</ref>
⚫
** [[Daiya]] <small>(Acq 2017)</small><ref>{{Cite web|url=https://www.fooddive.com/news/plant-based-food-firm-daiya-bought-for-32597m-by-pharma-company-otsuka/448160/|title=Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka|website=Food Dive}}</ref>
⚫
** ReCor Medical, Inc. <small>(Acq 2019)</small><ref>{{Cite web|url=https://www.biospace.com/article/otsuka-medical-devices-otsuka-holdings-and-recor-medical-announce-signing-of-merger-agreement/|title=Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement|website=BioSpace}}</ref>
** Otsuka America, Inc
*** Visterra <small>(Acq 2019)</small><ref>{{Cite web|url=https://www.genengnews.com/topics/drug-discovery/otsuka-to-acquire-visterra-for-430m-adding-to-its-pipeline-and-platforms/|title=Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms|date=July 11, 2018}}</ref>
*** Neurovance, Inc <small>(Acq 2017)</small><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/otsuka-to-buy-neurovance-for-up-to-250m-to-acquire-phase-iii-ready-adhd-drug/81253967|title=Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN|website=GEN|date=3 March 2017 |access-date=23 April 2018}}</ref>
*** Mindset Pharma Inc <small>(Acq 2023)</small>
*** Jnana Therapeutics Inc. <small>(Acq 2024)</small><ref>{{cite web|url=https://www.jnanatx.com/otsuka-pharmaceutical-completes-acquisition-of-jnana-therapeutics-inc/|title=Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.|website=GEN|date=23 September 2024 |access-date=2 October 2024}}</ref>
{{Tree list/end}}
{{hidden end}}


==Products==
==Products==
⚫
[[File:Products of Otsuka Pharmaceutical.jpg|thumb|Products of Otsuka Pharmaceutical]]
* [[CalorieMate]]
* [[CalorieMate]]
* [[Pocari Sweat]]
* [[Pocari Sweat]]
* [[Oronamin C]]
* [[Oronamin C]]
* [[Aripiprazole|Aripiprazole / Abilify]]<ref name=Adis2019>{{cite web |title=Aripiprazole |url=http://adisinsight.springer.com/drugs/800001612 |publisher=AdisInsight |access-date=4 June 2017}}</ref><ref>{{cite book |last1=Behere |first1=Prakash B. |last2=Das |first2=Anweshak |last3=Behere |first3=Aniruddh P. |title=Clinical Psychopharmacology: An Update |date=2018 |publisher=Springer |isbn=9789811320927 |page=66 |url=https://books.google.com/books?id=i9p1DwAAQBAJ&pg=PA66 }}</ref>
* [[Aripiprazole|Aripiprazole / Abilify]]<ref>{{cite web |title=Aripiprazole |url=http://adisinsight.springer.com/drugs/800001612 |publisher=AdisInsight |access-date=4 June 2017}}</ref><ref>{{cite book |last1=Behere |first1=Prakash B. |last2=Das |first2=Anweshak |last3=Behere |first3=Aniruddh P. |title=Clinical Psychopharmacology: An Update |date=2018 |publisher=Springer |isbn=9789811320927 |page=66 |url=https://books.google.com/books?id=i9p1DwAAQBAJ&pg=PA66 }}</ref>
* [[Rejoyn]]

*SoyJoy
== Otsuka Holdings Co. Ltd. Holdings ==

⚫
In 1990, Otsuka Holdings Co. Ltd. acquired [[Crystal Geyser Water Company]].<ref>[https://www.otsuka.com/en/ir/library/pdf/2014/2014_07.pdf Otsuka.com Library], ''Otsuka Pharmaceutical''. Retrieved September 21, 2019.</ref>

⚫
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".<ref name=biospace>{{Citation |date=January 13, 2012 |publisher=[[BioSpace]] |title=Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead |url=http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |access-date=January 15, 2012 |archive-url=https://web.archive.org/web/20160303182456/http://www.biospace.com/news_story.aspx?NewsEntityId=246332 |archive-date=March 3, 2016 |url-status=dead }}</ref> This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area.<ref>{{Citation |date=January 13, 2012 |access-date=January 15, 2012|title=UCB and Otsuka to focus collaboration on CNS disorders |at=zenopa.com |publisher=[[Zenopa]]|url=http://www.zenopa.com/news/801263654/UCB_and_Otsuka_to_focus_collaboration_on_CNS_disorders }}</ref>

⚫
In September 2013, Otsuka Holdings it acquired [[Astex|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news| url= https://www.reuters.com/article/2013/09/05/us-astex-offer-otsuka-idUSBRE98407Q20130905| title= Japan's Otsuka to buy cancer drug maker Astex Pharma| author= Tim Kelly| publisher=Reuters | date=5 September 2013}}</ref>

⚫
In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.<ref>{{cite web|url=https://dealbook.nytimes.com/2014/12/02/otsuka-of-japan-to-buy-avanir-pharmaceuticals-for-3-5-billion/?module=BlogPost-Title&version=Blog+Main&contentCollection=Mergers+&+Acquisitions&action=Click&pgtype=Blogs&region=Body|title=Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion|first=Jonathan|last=Soble|website=nytimes.com|access-date=23 April 2018}}</ref>

⚫
In July 2018, Otsuka Holdings acquired renal-focused ReCor Medical, Inc.<ref>{{Cite web|url=https://www.biospace.com/article/otsuka-medical-devices-otsuka-holdings-and-recor-medical-announce-signing-of-merger-agreement/|title=Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement|website=BioSpace}}</ref>


==References==
==References==
Line 95: Line 104:


==External links==
==External links==
*{{in lang|ja}} [http://www.otsuka.co.jp/ Otsuka Pharmaceutical Company, Limited.]
* {{in lang|ja}} [http://www.otsuka.co.jp/ Otsuka Pharmaceutical Company, Limited.]
*(in English) [https://www.otsuka.com/en/ir/library/pdf/2017/2017_a4.pdf Otsuka Integrated Report 2017]
* {{in lang|en}} [https://www.otsuka.com/en/ir/library/pdf/2017/2017_a4.pdf Otsuka Integrated Report 2017] (PDF) ({{Webarchive|url=https://web.archive.org/web/20210525104912/https://www.otsuka.com/en/ir/library/pdf/2017/2017_a4.pdf |date=2021-05-25 }})


{{TOPIX 100}}
{{TOPIX 100}}

Latest revision as of 00:53, 3 October 2024

Otsuka Pharmaceutical Co., Ltd.
Native name
大塚製薬株式会社
Ōtsuka Seiyaku Kabushiki-gaisha
Company typePublic KK
TYO: 4578
TOPIX 100 Component
IndustryPharmaceutical
Founded1921; 103 years ago (1921) (Founded)
1964 (Incorporated)
FounderBusaburo Otsuka
Headquarters
Chiyoda, Tokyo
,
Japan
Number of locations
69
Area served
Worldwide
Key people
Tatsuo Higuchi (President)
Revenue¥ 1.74 trillion (2022)
¥ 150.32 billion (2022)
OwnerNomura Trust and Banking investment trusts (11.43%)
and investment trusts managed by other banks
Number of employees
5,634 (2017)
ParentOtsuka Holdings Co. Ltd
Websiteotsuka.com

Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.

History

[edit]

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company.[1] The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.[1]

Otsuka Pharmaceutical Co. Ltd Holdings

[edit]

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.[2]

In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.[3]

In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".[4] This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.[5]

In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.[6]

In 2023, the company announced the acquisition of Mindset Pharma for $58.6 million.[7]

Acquisition history

[edit]
Otsuka Pharmaceutical Acquisitions

Products

[edit]
Products of Otsuka Pharmaceutical

References

[edit]
  1. ^ a b Fujita, Junko; Slodkowski, Antoni (December 16, 2010). Layne, Nathan (ed.). "Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1". Reuters. Archived from the original on March 4, 2012. Retrieved January 15, 2012.
  2. ^ "Tokushima Vortis". 15 January 2020. Retrieved October 30, 2020.
  3. ^ "Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A." otsuka.co.jp. May 28, 2008. Retrieved October 30, 2020.
  4. ^ Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead, BioSpace, January 13, 2012, archived from the original on March 3, 2016, retrieved January 15, 2012
  5. ^ UCB and Otsuka to focus collaboration on CNS disorders, Zenopa, January 13, 2012, retrieved January 15, 2012
  6. ^ "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. 3 March 2017. Retrieved 23 April 2018.
  7. ^ Howes, Laura (September 9, 2023). "Otsuka to buy Mindset Pharma". Chemical & Engineering News. Retrieved June 1, 2024.
  8. ^ "Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 | Otsuka People Talk".
  9. ^ Otsuka.com Library Archived 2019-06-16 at the Wayback Machine, Otsuka Pharmaceutical. Retrieved September 21, 2019.
  10. ^ Kelly, Tim (September 5, 2013). "Japan's Otsuka to buy U.S. cancer firm Astex for $886 million". Reuters.
  11. ^ Soble, Jonathan (2 December 2014). "Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion". The New York Times. Retrieved 23 April 2018.
  12. ^ "Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka". Food Dive.
  13. ^ "Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement". BioSpace.
  14. ^ "Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms". July 11, 2018.
  15. ^ "Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN". GEN. 3 March 2017. Retrieved 23 April 2018.
  16. ^ "Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc". GEN. 23 September 2024. Retrieved 2 October 2024.
  17. ^ "Aripiprazole". AdisInsight. Retrieved 4 June 2017.
  18. ^ Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927.
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Otsuka_Pharmaceutical&oldid=1249073971"